Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 4, 2009, Pages 483-484

  Daulat, S ^a   Detweiler, J G ^b   Pandya, A G ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b ProPath Laboratory   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HUMAN; INSOMNIA; LETTER; MALE; PATHOGENESIS; PEMPHIGUS VULGARIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; SKIN BIOPSY; ULTRAVIOLET B RADIATION; WEAKNESS; WEIGHT GAIN;

HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PEMPHIGUS; PHOTOTHERAPY; PREDNISONE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62149099897     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02929.x     Document Type: Letter

References (5)

1. Ameglio F, D'Auria L, Cordiali-Fei P et al. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 1999 13 : 220 224.
2. Feliciani C, Toto P, Amerio P et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis, J Invest Dermatol 2000 114 : 71 77.
3. Alecu M, Alecu S, Coman G, Galatescu E, Ursaciuc C. ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol 1999 58 : 121 130.
4. Study of etanercept (Enbrel) in the treatment of pemphigus vulgaris. ClinicalTrials.gov. Accessed July 27, 2007.
5. Jacobi A, Schuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-α inhibitor infliximab. Br J Dermatol 2005 153 : 448 449. doi:.